via AP Images)President Donald Trump makes an announcement about autism with National Institutes of Health Director Jay Bhattacharya, Food and Drug Administration Commissioner Marty Makary, Secretary of Health and Human Services Robert Kennedy Jr., and Medicare Services Administration Mehmet Oz in the Roosevelt Room of the White House, in Washington on Sept. 22, 2025. Francis Chung/POLITICO

...

Gabe Whisnant

By Gabe Whisnant

News Editor

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


Federal regulators have approved a second generic version of the abortion pill mifepristone, a routine step that quickly drew backlash from anti-abortion groups and some Republican lawmakers.

Drugmaker Evita Solutions announced on its website that the Food and Drug Administration had cleared its low-cost version of the pill, which is approved to end pregnancies up to 10 weeks.

Why It Matters

Mifepristone was first approved in 2000 and has been gradually made more accessible. The FDA authorized the first generic version, manufactured by GenBioPro, in 2019. Two years later, under Democratic President Joe Biden, the agency permitted telehealth prescribing and mail-order delivery of the drug, a policy shift that dramatically expanded access. Abortion opponents have been challenging that decision in court ever since.

Read More on Politics

via AP Images)President Donald Trump makes an announcement about autism with National Institutes of Health Director Jay Bhattacharya, Food and Drug Administration Commissioner Marty Makary, Secretary of Health and Human Services Robert Kennedy Jr., and Medicare Services Administration Mehmet Oz in the Roosevelt Room of the White House, in Washington on Sept. 22, 2025. Francis Chung/POLITICO

...

What to Know

In a letter to Republican attorneys general last month, Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Dr. Marty Makary pledged to conduct a full review of mifepristone, which was approved 25 years ago and has repeatedly been deemed safe and effective by FDA scientists.

Generic approvals are usually considered routine. After the patent on the original drug expires, multiple drugmakers often enter the market with cheaper versions. To receive approval, companies must demonstrate that their product is chemically identical to the original. In most cases, such reviews are completed within 10 months.

But Evita’s application took far longer. According to FDA filings, the company submitted its request four years ago. The FDA did not explain the delay.

Evita did not immediately respond to requests for comment. On its website, the privately held company says it “believes that all people should have access to safe, affordable, high-quality, effective, and compassionate abortion care.”

Major medical groups, including the American Medical Association, oppose restrictions on the pill, saying they are not supported by scientific evidence.

Conservatives on social media immediately lashed out at the news.

What People Are Saying

Students for Life Action, which opposes abortion, in a statement Thursday called the approval “a stain on the Trump presidency and another sign that the deep state at the FDA must go.”

Republican Sen. Josh Hawley of Missouri also criticized the move in a post on X, stating: “I have lost confidence in the leadership at FDA.”

Reproductive Freedom for All account posted on X, The FDA approved a new generic version of mifepristone, a pill that has been safely and effectively used in abortion and miscarriage care for over two decades. Thank you to the civil servants who made this happen."

What Happens Next

Approval of Evita’s pill is not expected to significantly alter access to mifepristone. The medication is typically prescribed with misoprostol, a second drug that causes the uterus to contract and empty. Together, the two drugs account for roughly two-thirds of U.S. abortions. Mifepristone blocks the hormone progesterone and softens the cervix to prepare the body for expulsion.

Still, access to the regimen remains sharply limited in many states. Abortion bans — including bans on medication abortion — have been enacted across large parts of the country. Other states have passed restrictions specific to mifepristone. Those measures remain tied up in ongoing legal challenges.

In August, Costco Wholesale cited low demand and announced it would not sell mifepristone in its U.S. pharmacy stores.

Updates: 10/2/25, 5:27 p.m. ET: This article was updated with new information and remarks.

Updates: 10/2/25, 7:19 p.m. ET: This article was updated with new information and remarks.

This article includes reporting by the Associated Press.

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines